The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

Author:Shweta Raskar, Business Development Specialist, Prophecy Market InsightsIntroductionThe Multi-Cancer Early Detection (MCED) Market is witnessing an unprecedented surge as diagnostic ...

Love & Joy Family Clinic announced an expansion of its screening offerings that strengthens the practice's cancer screenin ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with 95% accuracy ...

The oncology companion diagnostic market is projected to grow at a CAGR of ~10% over the forecast period. The market is driven by the growing adoption of precision medicine, rising cancer incidence, ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

Liquid biopsy is a noninvasive diagnostic tool that evaluates biomarkers in the blood and other body fluids. "Noninvasive" means that the sample for the liquid biopsy can be obtained with just a ...